Boston Scientific Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Portfolio Pulse from Benzinga Insights
Boston Scientific (NYSE:BSX) has been rated by 8 analysts over the last three months, with a mix of bullish and somewhat bullish opinions. The average 12-month price target is now $63.00, up from $60.62, with a high estimate of $66.00 and a low of $60.00. Analysts from firms like BTIG, Wells Fargo, Truist Securities, TD Cowen, Morgan Stanley, Canaccord Genuity, and Needham have maintained or adjusted their ratings and price targets. Boston Scientific specializes in less invasive medical devices and has a strong market presence with a high market cap and revenue growth, but faces challenges in ROE and ROA.
December 29, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific has received a mix of bullish and somewhat bullish ratings from analysts, with an increased average price target of $63.00. The company has a strong market presence and revenue growth, but ROE and ROA are below industry averages.
The positive sentiment from analysts, reflected in the increased average price target, suggests confidence in Boston Scientific's future performance. This could lead to a short-term positive impact on the stock price. However, the challenges in ROE and ROA may temper the impact, as they indicate potential underlying issues in financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100